KR102213286B1 - Medicinal herbs composition for treating vaginitis and preventing Cervical intraepithelial neoplasia - Google Patents

Medicinal herbs composition for treating vaginitis and preventing Cervical intraepithelial neoplasia Download PDF

Info

Publication number
KR102213286B1
KR102213286B1 KR1020200095649A KR20200095649A KR102213286B1 KR 102213286 B1 KR102213286 B1 KR 102213286B1 KR 1020200095649 A KR1020200095649 A KR 1020200095649A KR 20200095649 A KR20200095649 A KR 20200095649A KR 102213286 B1 KR102213286 B1 KR 102213286B1
Authority
KR
South Korea
Prior art keywords
vaginitis
weight
parts
itching
present
Prior art date
Application number
KR1020200095649A
Other languages
Korean (ko)
Inventor
정소영
Original Assignee
정소영
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 정소영 filed Critical 정소영
Priority to KR1020200095649A priority Critical patent/KR102213286B1/en
Application granted granted Critical
Publication of KR102213286B1 publication Critical patent/KR102213286B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/899Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A61K36/8994Coix (Job's tears)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284Atractylodes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/489Sophora, e.g. necklacepod or mamani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/75Rutaceae (Rue family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to an herbal medicine composition for treating vaginitis and preventing uterine cervical dysplasia. More specifically, the present invention contains a hot water extract of a mixture including Coix lachryma-jobi var. mayuen, Atractylodes lancea, Dictamnus dasycarpus, and Sophora flavescens as an active component. The herbal medicine composition according to the present invention has an advantage of effectively preventing uterine cervical dysplasia by effectively treating and preventing bacterial vaginosis and Candida vaginitis. In addition, the herbal medicine composition has no toxicity or side effects, and has excellent safety, thereby being able to be used as herbal preparations, pharmaceuticals, and health foods.

Description

질염의 치료 및 자궁경부이형성증의 예방용 한약 조성물{Medicinal herbs composition for treating vaginitis and preventing Cervical intraepithelial neoplasia}Herbal medicine composition for treating vaginitis and preventing Cervical intraepithelial neoplasia}

본 발명은 질염의 치료 및 자궁경부이형성증의 예방용 한약 조성물에 관한 것으로, 더욱 상세하게는 질염을 효과적으로 치료함으로써, 인유두종바이러스(humanpapillomavirus,HPV) 감염을 예방하고, 자궁경부이형성증(Cervical intraepithelial neoplasia CIN) 발생을 예방하는 질염의 치료 및 자궁경부이형성증의 예방용 한약 조성물에 관한 것이다.The present invention relates to an herbal composition for the treatment of vaginitis and the prevention of cervical dysplasia, and more specifically, by effectively treating vaginitis, preventing humanpapillomavirus (HPV) infection, and cervical intraepithelial neoplasia CIN It relates to an herbal composition for the treatment of vaginitis preventing the occurrence and prevention of cervical dysplasia.

가임기 여성에서 발생하는 질염의 90% 이상은 세균성 질증, 칸디다성 질염, 트리코모나스질염이며 이중 세균성 질증이 40~50%를 차지한다. 이런 균들은 여성의 질 내부가 정상 산도일 때는 증식하지 못하다가 과로나 스트레스, 피임약 복용 등으로 몸상태가 정상이 아닐 때 쉽게 침입해 수술 후 감염 등의 합병증을 높이고 산과적으로도 조기양막파수나 조기진통 등의 합병증이 발생할 수 있기 때문에 주의를 요하고 효과적인 치료를 하여야 한다.More than 90% of vaginitis that occurs in women of childbearing age are bacterial vaginosis, candidal vaginosis, and trichomonas vaginitis, of which 40-50% are bacterial vaginosis. These bacteria cannot proliferate when the inside of a woman's vagina is normal, but easily invade when the body is not normal due to overwork, stress, or taking contraceptives, increasing complications such as infection after surgery, and even obstetrically Since complications such as early labor may occur, care should be taken and effective treatment should be performed.

여성의 질은 천연적으로 다양한 세균, 효모 및 미생물에 의해서 군락화된다. 예를 들어, 정상적인 여성의 질에는 일반적으로 질 물질의 밀리리터당 약 104 이상의 유산균(Lactobacillus spp)이 포함되어 있다. 정상적인 조건하에서 질 세균총은 병원성 미생물의 침범에 대항하는 보호를 도와주는 약한 산성 환경을 제공한다. The female vagina is naturally colonized by a variety of bacteria, yeasts and microorganisms. For example, a normal woman's vagina typically contains about 10 4 or more Lactobacillus spp per milliliter of vaginal material. Under normal conditions, the vaginal flora provides a weakly acidic environment that helps protect against the invasion of pathogenic microorganisms.

그러나 상기와 같은 정상적인 조건 하에서 질 세균총 즉, 질 평형은 궁극적으로 질 감염을 유도하는 다양한 외부 인자에 의해서 쉽게 전복될 수 있다. 질 감염은 임상적 증후군이며 주로 세균성 질증, 칸디다 질염 및 트리코모나스 질염 등이 보고되어 있는데, 이 중 가장 흔한 질염은 세균성 질염이다.However, under normal conditions as described above, the vaginal flora, that is, vaginal equilibrium, can be easily overturned by various external factors that ultimately induce vaginal infection. Vaginal infection is a clinical syndrome and mainly bacterial vaginosis, Candida vaginitis, and Trichomonas vaginitis have been reported. Among these, the most common vaginitis is bacterial vaginosis.

상기 세균성 질증은 주로 질 내에서 유산균의 감소를 수반하는 혐기성 유기체 수의 증가에 의해서 야기되는 것으로 보고되어 있고, 이 외에도 세균이나 바이러스 감염, 항생제 복용이나 피임약 복용, 과다한 질 세정제 사용 등에 의해서도 발병할 수 있는 것으로 보고되어 있다. 질 내에서 유산균의 수가 감소하는 것은 영양소에 대한경쟁을 감소시키고, 존재하는 락트산의 양을 감소시켜 pH를 상승시키게 되며, 질 내에서 그의 성장이 통상적으로 억제되는 기회감염성 병원체(opportunistic pathogen)의 증식이 일어나게 돼서 발병된다. The bacterial vaginosis is reported to be mainly caused by an increase in the number of anaerobic organisms accompanied by a decrease in lactic acid bacteria in the vagina.In addition, it can be caused by bacterial or viral infections, taking antibiotics or contraceptives, and using excessive vaginal cleansing agents. It is reported to be. Decreasing the number of lactic acid bacteria in the vagina decreases competition for nutrients, increases the pH by reducing the amount of lactic acid present, and proliferation of opportunistic pathogens whose growth is normally inhibited in the vagina. It is caused by this.

상기와 같은 병원체의 증식이 일어나게 되어 발병하는 세균성 질증과 연관된 주요 병원체는 가드네렐라 바지날리스(Gardnerella vaginalis)인 것으로 보고되어 있다. 상기 가드네렐라 바지날리스의 감염에 의한 세균성 질증의 증상은 일반적으로 냉에서 특유의 불쾌한 냄새가 나고, 속옷을 적실 정도로 냉이 많아지며, 질의 분비물 즉, 묽은 균질의 분비물이 많아지고, 질 내 pH가 약 50 이상으로 상승하며, 가려움증이 발생하고, 그람-간병성 간균으로 코팅된 질 상피세포인 가드네렐라 단서세포(Gardnerella crue cells)의 존재를 포함하게 된다. 질(vagina)은 7~9cm 길이의 관으로 외부성기로부터 자궁경부와 연결되어 있다. 질의 입구는 배뇨구와 항문의 중간에 위치하고 있으며 자궁경부에서 분비되는 물질의 배설통로의 작용을 한다. 성인여성의 질에는 다양한 균이 정상적으로 서식하고 있는데, Lactobacillus, Streptococcus, Staphylococcus가 포함된다. 혐기성 균과 호기성균의 서식비율은 5:1 정도이며 약 20%의 여성에서는 진균류인 Candida균이 정상적으로 질에서 발견된다. 서식균주의 종류는 질의 glycogen 및 glucose의 함량, pH 등에 의해 영향을 받는다. It has been reported that the major pathogen associated with bacterial vaginosis caused by the proliferation of the above pathogens is Gardnerella vaginalis. Symptoms of bacterial vaginosis caused by infection of the Gardnerella vaginalis generally have a characteristic unpleasant odor in cold, and cold enough to wet underwear, vaginal secretions, that is, watery, homogeneous secretions, and vaginal pH Rises above about 50, itching occurs, and includes the presence of Gardnerella crue cells, vaginal epithelial cells coated with Gram-carriing bacillus. The vagina is a 7~9cm long tube that is connected to the cervix from the external genitalia. The entrance to the vagina is located in the middle of the urinary tract and anus, and acts as an excretory passage for substances secreted from the cervix. Various bacteria are normally inhabiting the vagina of adult women, including Lactobacillus, Streptococcus, and Staphylococcus. The inhabitation ratio between anaerobic and aerobic bacteria is about 5:1, and in about 20% of women, the fungus Candida is normally found in the vagina. The type of inhabited strain is affected by the content of glycogen and glucose in the vagina, and the pH.

정상적인 질의 pH는 45~51이다. 질의 내부가 산성인 이유는 질 내 서식균과 질 상피세포가 glycogen 및 glucose를 이용하여 유산(lactic acid)을 생산해 내기 때문이다. 질내에 서식하는 유산균은 젖산(lactic acid)을 생산하여 pH를 유지하여 유해균의 번식을 억제하는 유용한 역할을 한다. The normal vaginal pH is 45-51. The reason why the interior of the vagina is acidic is that the vaginal bacteria and vaginal epithelial cells produce lactic acid using glycogen and glucose. Lactobacillus living in the vagina plays a useful role in suppressing the reproduction of harmful bacteria by maintaining the pH by producing lactic acid.

세균성 질염은 가장 흔한 질의 염증원인이며, 성관계를 통해 감염되는지의 여부는 명확하지 않다. 그러나 세균성 질염이 임질, 클라미디아 감염 등 성병 감염질환과 관련이 있다는 보고가 있다. 세균성 질염은 질내 정상균 중 유산균의 번식정도가 감소하여 질 내의 정상균 중 혐기성균이 과번식함으로 해서 발생한다. 원인이 되는 균주로는 Gadnerella vaginalis, Peptostreptococcus, Mobiluncus, Bacteroides 등이 있다. 대표적인 증상으로는 질 분비물의 증가와 분비물이 색을 띠며(흰색 또는 엷은 황색, 녹색, 회색 등) 비린 냄새가 나는 것이다. 특징적인 냄새는 과번식한 균에 의해 생성된 방향성 아민이 원인이다.Bacterial vaginosis is the most common cause of vaginal inflammation, and it is not clear whether it is infected through sexual intercourse. However, there are reports that bacterial vaginosis is related to sexually transmitted diseases such as gonorrhea and chlamydia infection. Bacterial vaginosis is caused by over-proliferation of anaerobic bacteria among normal bacteria in the vagina due to a decrease in the propagation degree of lactic acid bacteria among normal bacteria in the vagina. The causative strains include Gadnerella vaginalis, Peptostreptococcus, Mobiluncus, and Bacteroides. Typical symptoms include an increase in vaginal discharge and a color (white or pale yellow, green, gray, etc.) and a fishy odor. The characteristic odor is caused by aromatic amines produced by overgrown bacteria.

상기와 같은 질염을 예방하고 치료하기 위한 질염 치료 방법이 많이 연구되어왔다. 근래에는 질의 세균 감염에 대한 치료 방법으로 메트로니다졸(Metronidazole)과 같은 질염 치료제를 경구 투여하거나 크림 형태로 투여하는 방법을 일반적으로 사용하고 있다. 그런, 상기 메트로니다졸과 같은 광범위 스펙트럼의 항생제의 사용은 항생제 내성이라는 문제점을 내포할 뿐만 아니라, 상기와 같은 항생제의 사용은 유익한 유산균을 포함한 질 내의 광범위한 정상 세균총을 사멸시킬 수 있기 때문에 바람직하지 않은 것으로 평가되고 있다.A lot of research has been done on a vaginitis treatment method to prevent and treat such vaginitis. Recently, as a treatment method for a bacterial infection of the vagina, a method of administering a vaginitis treatment such as metronidazole orally or in the form of a cream has been generally used. However, the use of broad-spectrum antibiotics such as metronidazole not only implies the problem of antibiotic resistance, but also the use of such antibiotics is evaluated as undesirable because it can kill a wide range of normal bacteria in the vagina including beneficial lactic acid bacteria. Has become.

한편, 이러한 유산균을 포함한 질 내 정상 세균총의 사멸은 이차적인 합병증을 야기할 수 있는 것으로 보고되어있다. 즉, 질 내에서 다양한 기회감염성 병원체를 억제하는 유산균의 감소는 질 내의 pH가 증가 되어 산성 환경의 유지가 힘들어지므로, 혐기성균 증식에 의한 감염을 가속화시켜 추가적인 감염의 원인이 될 수 있다.On the other hand, it has been reported that the killing of normal vaginal flora including these lactic acid bacteria may cause secondary complications. In other words, the decrease of lactic acid bacteria that inhibit various opportunistic pathogens in the vagina increases the pH in the vagina, making it difficult to maintain an acidic environment, and thus accelerates infection by anaerobic bacteria proliferation and may cause additional infection.

그 예로서 상기 세균성 질염의 잦은 감염은 자궁경부이형성증(Cervical intraepithelial neoplasia,CIN)의 원인이 될 수 있는바, 상기 자궁경부이형성증은 자궁경부암의 전암병변으로서 인유두종 바이러스(humanpapillomavirus,HPV) 감염이 주된 원인이며, 이러한 HPV 감염은 상기 질 내 정상 세균총의 사멸에 의한 이차적인 합병증으로 야기될 수 있는 것이다.As an example, frequent infection of the bacterial vaginosis may be the cause of cervical dysplasia (CIN), and the cervical dysplasia is a precancerous lesion of cervical cancer, mainly due to infection with human papillomavirus (HPV). And, such HPV infection may be caused by secondary complications due to the death of the normal flora in the vagina.

따라서, 상기 CIN 및 HPV를 효과적으로 예방하고, 질 감염을 억제 및/또는 치료할 수 있는 부작용이 문제되지 아니하는 안전한 질염 예방 또는 치료 조성물을 개발하는 것이 시급한 실정이다.Therefore, it is urgent to develop a safe vaginitis prevention or treatment composition that effectively prevents the CIN and HPV, suppresses and/or treats vaginal infection, and does not have side effects.

KR 10-2014810 B1KR 10-2014810 B1 KR 10-1771479 B1KR 10-1771479 B1 KR 10-1133723 B1KR 10-1133723 B1

본 발명의 목적은 의이인, 창출, 백선피 및 고삼의 혼합 추출물을 포함하는 한약 조성물을 제공함으로써, 황색포도상구균(Staphylococcus aureus)에 대한 항균 및 칸디다 알비칸스(Candida albicans)에 대한 항진균 활성을 통해 질염을 효과적으로 예방 및 치료하는 질염의 치료 및 자궁경부이형성증의 예방용 한약 조성물을 제공하는 데 있다. An object of the present invention is to provide an herbal composition comprising a mixed extract of Uiyiin, Jeonju, Baekseonpi and Gosam, thereby antibacterial against Staphylococcus aureus and antifungal activity against Candida albicans. It is to provide an herbal composition for the treatment of vaginitis and prevention of cervical dysplasia to effectively prevent and treat.

본 발명의 다른 목적은 질염을 효과적을 예방 및 치료함으로써, 자궁경부이형성증 역시 효과적으로 예방할 수 있는 질염의 치료 및 자궁경부이형성증의 예방용 한약 조성물을 제공하는 데 있다. Another object of the present invention is to provide an herbal composition for treating vaginitis and preventing cervical dysplasia, which can effectively prevent cervical dysplasia by effectively preventing and treating vaginitis.

상기한 목적을 달성하기 위한 본 발명의 질염의 치료 및 자궁경부이형성증의 예방용 한약 조성물은, 의이인, 창출, 백선피 및 고삼의 혼합물의 열수추출물을 유효성분으로 포함하는 것을 특징으로 한다.The herbal composition for the treatment of vaginitis and the prevention of cervical dysplasia of the present invention for achieving the above object is characterized in that it comprises a hot water extract of a mixture of Ui-in, Jeon, tinea and Gosam as an active ingredient.

상기 열수추출물은, 상기 의이인 100중량부, 창출 50~70중량부, 백선피 30~40중량부 및 고삼 30~40중량부를 혼합한 후, 이를 물을 용매로 하여 50~130℃에서 3~24시간 추출한 것임을 특징으로 한다.The hot water extract is mixed with 100 parts by weight of the above, 50 to 70 parts by weight of creation, 30 to 40 parts by weight of Baekseonpi, and 30 to 40 parts by weight of Gosam, and then 3 to 24 at 50 to 130°C using water as a solvent. It is characterized by time extraction.

상기 한약 조성물은, 황색포도상구균(Staphylococcus aureus)과 가드네렐라 바지날리스균(Gardnerella vaginalis)에 대한 항균활성 및 칸디다 알비칸스(Candida albicans)에 대한 항진균활성을 갖는 것을 특징으로 한다. The herbal composition is characterized by having an antibacterial activity against Staphylococcus aureus and Gardnerella vaginalis and an antifungal activity against Candida albicans.

본 발명에 의한 한약 조성물은, 세균성 질염 및 칸디다성 질염을 효과적으로 치료 및 예방함으로써, 자궁경부이형성증 역시 효과적으로 예방할 수 있다는 장점이 있다. 또한, 독성이나 부작용이 전혀 없고 안전성이 우수하여 한약 제제, 의약품 및 건강식품으로서 활용이 가능하다는 장점이 있다. The herbal composition according to the present invention has the advantage of being able to effectively prevent cervical dysplasia by effectively treating and preventing bacterial vaginosis and candidal vaginitis. In addition, there is no toxicity or side effects, and excellent safety, so it has the advantage that it can be used as a herbal medicine preparation, medicine, and health food.

본 발명은 다양한 변경을 가할 수 있고 여러 가지 실시예를 가질 수 있는 바, 특정 실시예들을 예시하고 상세하게 설명하고자 한다. 그러나 이는 본 발명을 특정한 실시 형태에 대해 한정하려는 것이 아니며, 본 발명의 사상 및 기술 범위에 포함되는 모든 변경, 균등물 내지 대체물을 포함하는 것으로 이해되어야 한다.The present invention is intended to illustrate and describe specific embodiments as various changes may be made and various embodiments may be provided. However, this is not intended to limit the present invention to a specific embodiment, it is to be understood to include all changes, equivalents, or substitutes included in the spirit and scope of the present invention.

이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.

본 발명은 의이인, 창출, 백선피 및 고삼의 혼합물의 열수추출물을 유효성분으로 포함하는 질염의 치료 및 자궁경부이형성증의 예방용 한약 조성물에 관한 것이다. The present invention relates to an herbal composition for the treatment of vaginitis and the prevention of cervical dysplasia, comprising a hot water extract of a mixture of Ui-in, Cheong, Baekseonpi and Gosam as an active ingredient.

본 발명에서 사용되는 상기 의이인은 율무 열매의 껍질을 벗긴 알로서, 인체의 수분대사를 원활하게 시켜주는 효능을 가지며, 소화기를 도와주는 역할을 한다고 알려져 있다. 아울러, 항종양, 항혈당, 면역증강, 장관자궁억제, 진정, 진통, 해열 등의 약리작용이 알려져 있다. The uiyiin used in the present invention is a peeled egg of the adlay fruit, has an effect of smoothing the body's water metabolism, and is known to play a role in helping the digestive system. In addition, pharmacological actions such as anti-tumor, anti-glycemic, immunity enhancement, intestinal uterine inhibition, sedation, pain relief, and fever are known.

상기 창출은 삽주의 뿌리 열매를 말린 것으로, 위장을 튼튼하게 하고 비만을 방지한다고 알려져 있다. 또한, 몸속의 독과 통증을 없애는 효능이 있다고 알려져 있다.The creation is by drying the root fruit of Sapju, which is known to strengthen the stomach and prevent obesity. It is also known to be effective in removing poison and pain in the body.

상기 백선피는 운향과인 백선의 뿌리껍질을 말린 것으로, 피부발진, 습진, 풍진, 가려움증, 알레르기성 피부염 등에 사용되며, 해열작용과, 진균억제작용이 보고되었다. The ringworm peel is dried root bark of ringworm ringworm, and is used for skin rash, eczema, rubella, itching, allergic dermatitis, etc., and antipyretic action and fungal inhibitory action have been reported.

상기 고삼은 고삼의 뿌리를 말린 것으로, 항균, 소염, 이뇨작용이 보고되었다.The gosam is a dried root of gosam, and antibacterial, anti-inflammatory, and diuretic effects have been reported.

본 발명의 한약 조성물은 상기한 성분을 혼합한 혼합물을 열수 추출한 추출물을 유효성분으로 포함하는 것으로, 구체적으로 상기 의이인 100중량부, 창출 50~70중량부, 백선피 30~40중량부 및 고삼 30~40중량부를 혼합한 후, 이를 물을 용매로 하여 상압 또는 가압 상태에서 50~130℃의 온도로 3~24시간 추출한 추출물을 유효성분으로 포함한다. 이때, 상기 혼합비는 각 성분의 상보적 작용을 위한 것이다. 또한, 상기 추출물을 필요에 따라 여과, 농축 또는 건조할 수 있음은 당연한바, 이의 추가 실시를 제한하지 않는다.The herbal composition of the present invention comprises an extract obtained by extracting hot water from a mixture of the above ingredients as an active ingredient, and specifically, 100 parts by weight of Ui-in, 50 to 70 parts by weight of creation, 30 to 40 parts by weight of Baekseonpi and 30 of Gosam After mixing ~40 parts by weight, the extract, which is extracted with water as a solvent, at a temperature of 50 to 130°C under normal pressure or pressurization, for 3 to 24 hours is included as an active ingredient. At this time, the mixing ratio is for the complementary action of each component. In addition, it is natural that the extract can be filtered, concentrated or dried as necessary, and further implementation thereof is not limited.

본 발명의 한약 조성물은 이러한 성분의 혼합 추출을 통해 각 성분이 상보적인 작용을 함으로써, 황색포도상구균(Staphylococcus aureus)과 가드네렐라 바지날리스균(Gardnerella vaginalis)에 대한 항균활성 및 칸디다 알비칸스(Candida albicans)에 대한 항진균활성을 가져 여성의 질염을 효과적으로 예방 및 치료하는 것이다.The herbal composition of the present invention has an antibacterial activity against Staphylococcus aureus and Gardnerella vaginalis and Candida albicans ( It has antifungal activity against Candida albicans) to effectively prevent and treat vaginitis in women.

한편, 상기 황색포도상구균(Staphylococcus aureus)과 가드네렐라 바지날리스균(Gardnerella vaginalis)에 대한 항균활성 및 칸디다 알비칸스(Candida albicans)에 대한 항진균활성을 더욱 높이기 위하여, 상기 의이인, 창출, 백선피 및 고삼의 혼합물에 아레카야자 1~10중량부 및 무화과나무 1~10중량부를 더 혼합하여 열수추출할 수 있다.On the other hand, in order to further increase antibacterial activity against Staphylococcus aureus and Gardnerella vaginalis and antifungal activity against Candida albicans, the Ui-in, creation, ringworm And 1 to 10 parts by weight of areca palm and 1 to 10 parts by weight of fig tree may be further mixed with the mixture of Gosam to extract hot water.

상기 아레카야자(Chrysalidorcarpus lutescens)는 가시가 없는 야자의 일종인 공기정화식물로서, 그 잎을 건조한 것을 사용하며, 이를 통해 더욱 우수한 항균 및 항진균활성을 부여한다.The Areca palm (Chrysalidorcarpus lutescens) is an air-purifying plant, which is a kind of palm without thorns, and uses dried leaves, thereby imparting more excellent antibacterial and antifungal activity.

또한, 상기 무화과나무는 무화과나무의 잎을 건조한 것으로, 상기 무화과나무 역시 더욱 우수한 항균 및 항진균활성을 부여한다.In addition, the fig tree is the dried leaves of the fig tree, and the fig tree also imparts more excellent antibacterial and antifungal activity.

본 발명에 의한 한약 조성물은, 약학적 조성물로 사용될 수 있다.The herbal composition according to the present invention can be used as a pharmaceutical composition.

상기 약학적 조성물은 약학적 조성물에 통상 사용되어 냄새, 맛, 시각 등을 향상시킬 수 있는 성분을 추가로 포함할 수 있다. 또한, 본 발명의 약학적 조성물은 약학적으로 허용 가능한 첨가제를 추가적으로 포함할 수 있다. 약학적으로 허용 가능한 첨가제는 예컨대, 전분, 젤라틴화 전분, 미결정셀룰로오스, 유당, 포비돈, 콜로이달실리콘디옥사이드, 인산수소칼슘, 락토스, 만니톨, 엿, 아라비아고무, 전호화전분, 옥수수전분, 분말셀룰로오스, 히드록시프로필셀룰로오스, 오파드라이, 전분글리콜산나트륨, 카르나우바납, 합성규산알루미늄, 스테아린산, 스테아린산마그네슘, 스테아린산알루미늄, 스테아린산칼슘, 백당, 덱스트로스, 소르비톨 및 탈크 등이 있으나, 이를 한정하지 않는다The pharmaceutical composition may further include ingredients that are commonly used in pharmaceutical compositions to improve odor, taste, and vision. In addition, the pharmaceutical composition of the present invention may additionally contain a pharmaceutically acceptable additive. Pharmaceutically acceptable additives include, for example, starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, lactose, mannitol, syrup, gum arabic, pregelatinized starch, corn starch, powdered cellulose, Hydroxypropyl cellulose, Opadry, sodium starch glycolate, carnaubanap, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, sucrose, dextrose, sorbitol and talc, etc., but are not limited thereto.

본 발명의 상기 약학적 조성물은 약학적으로 허용 가능한 담체를 포함하고 경구용의 인체용으로 제형화될 수 있다. 본 발명의 약학적 조성물을 제제화하는 경우 충진제, 증량제, 결합제, 습윤제, 붕해제 및 계면활성제 등의 희석제 또는 부형제를 사용할 수 있다.The pharmaceutical composition of the present invention may contain a pharmaceutically acceptable carrier and may be formulated for oral use. When formulating the pharmaceutical composition of the present invention, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants and surfactants may be used.

아울러, 본 발명의 약학적 조성물의 복용량은 환자의 나이, 신체적 조건, 몸무게 등에 의해 다양화될 수 있지만, 일반적으로 1일 0.1~1000mg/kg의 양으로 1일 2~5회에 걸쳐 복용할 수 있다.In addition, the dosage of the pharmaceutical composition of the present invention can be varied depending on the patient's age, physical condition, weight, etc., but can be generally taken 2 to 5 times a day in an amount of 0.1 to 1000 mg/kg per day. have.

삭제delete

삭제delete

삭제delete

이하, 실시예를 통해 본 발명을 더욱 상세히 설명한다.Hereinafter, the present invention will be described in more detail through examples.

(실시예 1)(Example 1)

의이인 100중량부, 창출 60중량부, 백선피 35중량부 및 고삼 35중량부를 준비하여 정제수로 세척하고, 건조한 후, 분말화하였다. 그리고 이 약재들을 혼합하여 혼합물을 준비한 후, 이에 10중량배의 물을 가하고, 90℃에서 3시간 동안 열수추출하였다. 그리고 획득한 추출물을 여과하였다.Uiiin 100 parts by weight, creation 60 parts by weight, tinea skin 35 parts by weight, and gosam 35 parts by weight were prepared, washed with purified water, dried, and then powdered. Then, after preparing a mixture by mixing these medicinal materials, 10 times the amount of water was added thereto, and hot water extraction was performed at 90°C for 3 hours. And the obtained extract was filtered.

(실시예 2)(Example 2)

약재로서 아레카야자의 건잎 분말 10중량부 및 무화과나무의 건잎 분말 10중량부를 더 사용하였다.As medicinal materials, 10 parts by weight of dry leaf powder of Areca palm and 10 parts by weight of dry leaf powder of fig tree were further used.

(시험예 1) : 세포독성(Test Example 1): Cytotoxicity

MTT 용액은 살아있는 세포에서 미토콘드리아의 디하이드로게나아제(dehydrogenases)에 의해서 포르마잔(formazan)을 형성하여 세포의 생존 여부를 확인할 수 있다. The MTT solution forms formazan by mitochondrial dehydrogenases in living cells to confirm the survival of cells.

실시예 1 및 2에서 제조한 시료의 세포독성 여부를 확인하기 위하여, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 분석을 수행하였다. 이때, 실시예 1 및 2의 시료는 농축 및 동결건조하여 사용하였다.In order to confirm the cytotoxicity of the samples prepared in Examples 1 and 2, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) analysis was performed. At this time, the samples of Examples 1 and 2 were concentrated and lyophilized.

구체적으로, RAW 2647 세포를 96 웰 플레이트에 1×104cells/웰로 접종(seeding)한 후, 70% confluency까지 배양하였다. 그 후, DMSO에 녹인 시료를 50, 100, 300, 500 및 1000㎍/㎖의 농도로 각각 처리하고, 24시간 동안 배양하였다. 그 후, MTT 시약(0.2㎎/㎖)을 첨가하고. 2시간 동안 추가로 배양한 후, 배양액을 제거하고, 100㎕의 디메틸설폭사이드(dimethylsulfoxide)를 첨가한 후, microplate reader(Genios, Tecan, Austria)로 540nm에서 흡광도를 측정하여 세포 생존율(cell viability)을 결정하였다.Specifically, RAW 2647 cells were seeded in a 96-well plate at 1×10 4 cells/well, and then cultured to 70% confluency. Then, the samples dissolved in DMSO were treated at concentrations of 50, 100, 300, 500 and 1000 µg/ml, respectively, and cultured for 24 hours. Then, MTT reagent (0.2 mg/ml) was added. After culturing for an additional 2 hours, the culture medium was removed, 100 µl of dimethylsulfoxide was added, and the absorbance was measured at 540 nm with a microplate reader (Genios, Tecan, Austria) to determine cell viability. Was determined.

그 결과, 실시예 1 및 2는 500㎍/㎖까지 세포 생존율에 영향을 미치지 않는 것으로 확인되었다.As a result, it was confirmed that Examples 1 and 2 did not affect cell viability up to 500 μg/ml.

(시험예 2) :디스크 확산법에 의한 항균 및 항진균 효과 (Test Example 2): Antibacterial and antifungal effects by the disk diffusion method

실시예 1 및 2에서 제조한 시료의 항균 및 항진균 효과를 확인하기 위하여, 질 감염 균주에 대하여 디스크 확산법을 수행하였다. 이때, 실시예 1 및 2의 시료는 농축 및 동결건조하여 사용하였다.In order to confirm the antibacterial and antifungal effects of the samples prepared in Examples 1 and 2, the disc diffusion method was performed on the vaginal infection strain. At this time, the samples of Examples 1 and 2 were concentrated and lyophilized.

구체적으로, 황색포도상구균(Staphylococcus aureus), 칸디다 알비칸스(Candida albicans), 가드네렐라 바지날리스(]Gardnerella vaginalis)을 이용하여 공시된 디스크퓨전법을 이용하여 그 억제활성을 측정하였다. 억제활성은 균주를 한전배지에 106CFU가 되도록 접종하고 각 시료를 0.5%(w/w)가 되도록 주입한 후, 억제환의 크기를 측정하는 방식으로 하여 그 결과를 하기 표 1에 나타내었다.Specifically, the inhibitory activity was measured using the disclosed disc fusion method using Staphylococcus aureus, Candida albicans, and Gardnerella vaginalis. Inhibitory activity was inoculated to 10 6 CFU in KEPCO medium and each sample was injected to be 0.5% (w/w), and then the size of the inhibitory ring was measured, and the results are shown in Table 1 below.

시험예 2 결과Test Example 2 result 구분division 억제환의 크기(mm)_24시간 후Size of suppression ring (mm)_after 24 hours 황색포도상구균Staphylococcus aureus 칸디다 알비칸스Candida albicans 가드네렐라 바지날리스균Gardnerella parangalis bacteria 실시예 1Example 1 3636 2525 3131 실시예 2Example 2 4040 2828 3535 대조군Control 1515 1010 1212

상기와 같이 본 발명에 따른 실시예 1 및 실시예 2는 배지에 아무 것도 첨가하지 않은 대조군에 비하여 균주의 억제활성이 큰 것을 확인하여 질염을 예방 및 치료하는 효과가 클 것으로 예상된다.As described above, Examples 1 and 2 according to the present invention are expected to have a greater effect of preventing and treating vaginitis by confirming that the inhibitory activity of the strain is greater than that of the control group in which nothing is added to the medium.

(시험예 3)(Test Example 3)

실시예 1의 조성물을 대상으로 만성질염(1년 3회 이상 질염 증상이 나타나는 경우)으로 고통받는 여성 19명을 대상으로 테스트 하였다. The composition of Example 1 was tested on 19 women suffering from chronic vaginitis (when vaginitis symptoms appear more than 3 times a year).

처방으로는 하루 2번(아침과 저녁 식후) 실시예 1의 조성물 120ml를 60일간 복용토록 하고, 6개월 후 질염증상의 여, 부를 조사하였다. As a prescription, 120ml of the composition of Example 1 was taken twice a day (after breakfast and dinner) for 60 days, and after 6 months, the presence or absence of vaginitis was investigated.

그 결과는 하기 표 2에 나타내었다.The results are shown in Table 2 below.

시험예 3 결과Test Example 3 result 환자번호Patient number 처방 전 증상Prescription symptoms 처방 후After prescription 1One 매달생리끝날때마다 질염, 세균성질염으로 진단받음. 가려움이 심함.At the end of monthly menstruation, he is diagnosed with vaginitis or bacterial vaginosis. Severe itching. 생리 끝날 때에도 가려움 등의 질염 증상이 발생하지 않음.Even at the end of menstruation, symptoms of vaginitis such as itching do not occur. 0 0 22 자궁경부이형성증 진단받음, 잦은 질염으로 가려움 따가움 1년 3회 이상, 속옷이 젖을 정도로 분비물 많음. Diagnosed with cervical dysplasia, frequent vaginitis, itching, itching, more than 3 times a year, so much that the underwear gets wet. 질염으로 인한 가려움,따가움, 분비물 많은 증상 소실Itching, itching, and discharge from vaginitis disappear many symptoms 00 33 매달 질염으로 외음부가 붓고 가렵고, 하얀냉이 많이 나온다. HPV양성 진단받음. Monthly vaginitis causes swelling and itching of the vulva, and a lot of white radish comes out. Diagnosed positive for HPV. 질염 증상 소실Disappearance of vaginitis symptoms 00 44 잦은 질염으로 가려움 따가움 1년 3회이상, 속옷이 젖을 정도로 분비물 많음., 빈뇨Frequent vaginitis, itching, itching, more than 3 times a year, so much secretions that the underwear gets wet, frequent urination 질염으로 인한 가려움, 따가움, 분비물 많은 증상 소실Itching, itching, and discharge of many symptoms due to vaginitis 00 55 질염, 원래도 냉이 많고, 생리 때 가려움, 따가움 증가. 평소 팬티라이너 매일 하고 다님. Vaginitis, originally a lot of cold, itching and burning during menstruation. I usually wear a panty liner every day. 라이너 안하고 다녀도 되고, 증상 없어졌다가 다시 증상 생김You don't have to go without the liner, symptoms go away, then symptoms appear again 1One 66 이형성증1단계, 평소 잦은 질염으로 젖을 정도, 2달에 한번정도 증상Dysplasia stage 1, usually getting wet due to frequent vaginitis, symptoms about once every two months 질염으로 인한 분비물 없는 상태 2달 이상지속, 이형성증 고위험군 소실Vaginitis without discharge, lasting more than 2 months, high risk of dysplasia disappeared 00 77 자궁근종, 잦은 질염으로 가려움이 한 달에 2회 이상 있고 따가움은 생리 전에 있고, 분비물은 배란기가 아닐 때에도 많아서 소형패드를 하루 4,5개 정도 사용. Fibroids and frequent vaginitis cause itching more than twice a month, soreness before menstruation, and secretions even when not in ovulation, so use 4,5 small pads a day. 가려움 따가움 증상 소실Itching, itching symptoms disappear 00 88 질염, 가려움, 따가움, 젖을 정도로 많은 분비물, 다낭성난소Vaginitis, itching, itching, wet discharge, polycystic ovary 질염증상소실상태 3개월 이상 유지Vaginitis symptoms disappeared and maintained for more than 3 months 00 99 이형성증1단계(세포검사 아직 안 함), 잦은 질염, 매달 젖을 정도로 많은 분비물, 가려움, 따가움은 가끔. 자궁근종2cm. Stage 1 dysplasia (no cytology yet), frequent vaginitis, monthly wet discharge, itching, itching occasionally. Uterine fibroids 2 cm. 질염증상 없는 상태 6개월 이상 유지, 이형성증 정상진단Maintained for more than 6 months without vaginitis symptoms, normal diagnosis of dysplasia 00 1010 경과다, 잦은 질염-?디다균, 젖을 정도로 분비물 많음. 가려움, 따가움. 자궁내막증Elapsed, frequent vaginitis-?Dida bacteria, a lot of secretions enough to get wet. Itching, itching. Endometriosis 질염 증상 없는 상태 3개월 이상 유지Maintaining no symptoms of vaginitis for at least 3 months 00 1111 잦은 질염으로 1년에 3회 이상, 속옷이 젖을 정도로 분비물 많음, 자궁경부 이형성증 진단받음Frequent vaginitis, more than 3 times a year, too much secretion to wet underwear, and diagnosed with cervical dysplasia 질염증상소실Disappearance of vaginitis symptoms 00 1212 월경불순, 평소 잦은 질염으로 따갑고 가렵고 분비물 많은 편, 자궁경부 이형성증 2단계 진단받고 원추절제술 시행. 수술 이후에도 질염증상 반복,질염으로 인한 가려움, 따가움, 분비물 많은 증상 거의 소실됨 Menstrual irregularities, frequent vaginitis, sore, itchy, and a lot of discharge, cervical dysplasia stage 2 was diagnosed and cone resection was performed. Even after surgery, vaginitis symptoms repeat, itching, itching, and discharge from vaginitis are almost eliminated. 질염으로 인한 가려움, 따가움, 분비물 많은 증상 거의 소실됨 Itching, itching, and discharge from vaginitis almost disappear 00 1313 다낭성난소, 잦은 질염으로 외음부 가려움따가움, hpv양성Polycystic ovary, itchy vulva due to frequent vaginitis, HPV positive 질염으로 인한 외음부 가려움 따가움 증상 소실Itching of the vulva due to vaginitis disappears 00 1414 질염 자주, 칸디다, 가드렐라, 분비물이 엄청 심하다 Frequent vaginitis, candida, gadrella, very severe discharge 호전되었지만, 다시 증상 심하게 나타나고, 호악 반복됨Although improved, symptoms reappeared, and the symptoms were repeated. 1One 1515 빈뇨, 질염 자주 생김, 가려움, 따가움Frequent urination, vaginitis, itching, itching 빈뇨는 많이 호전되었지만 질염증상은 호악 반복Frequent urination improved a lot, but vaginitis symptoms were recurring 1One 1616 월경선기, 잦은 질염으로 팬티가 젖을 정도로 많은 분비물Menstrual period, frequent vaginitis, so much that the panties become wet 질염으로 인한 분비물 감소Reduced discharge from vaginitis 00 1717 한 달에 한번 질염계속 재발, 가렵고 냉 많이 나오고, 칸디다. 가드네라, 유레아플라즈마 진단. Once a month, vaginitis continues to recur, itchy and cold, and candida. Gardnera, diagnosed with ureaplasma. 약간 호전되었지만 증상 계속 있음Slight improvement, but symptoms persist 1One 1818 다낭성난소, 잦은 질염, 가려움 심함Polycystic ovary, frequent vaginitis, severe itching 질염 가려움 증상 소실Vaginitis itching symptoms disappear 00 1919 잦은 질염, 분비물 많음. 가드레넬라, 유레아플라즈마 양성Frequent vaginitis, abundant discharge. Guardrenella, urea plasma cultivation 질염 분비물 많은 증상 소실Vaginitis discharge many symptoms disappear 00 1: 질염 증상이 있음
0: 질염 증상이 없음
1: Has symptoms of vaginitis
0: No symptoms of vaginitis

상기 표 2에서 확인할 수 있는 바와 같이, 19명 중 실시예 1의 복용 후, 15명이 증상이 소실됨을 확인할 수 있었는바, 그 치료율은 78.94% 정도임을 확인할 수 있었다.As can be seen in Table 2, after taking Example 1 out of 19 patients, it was confirmed that the symptoms disappeared in 15 patients, and the treatment rate was about 78.94%.

(시험예 4)(Test Example 4)

실시예 1의 조성물을 대상으로 자궁경부이형성증 진단받는 여성 10명을 대상으로 테스트하였다. 처방으로는 하루 2번(아침과 저녁 식후) 실시예 1의 조성물 120ml를 60일간 복용토록 한 후, 6개월 후 자궁경부이형성증의 치료 여, 부를 조사하였다. The composition of Example 1 was tested on 10 women diagnosed with cervical dysplasia. As a prescription, 120ml of the composition of Example 1 was administered twice a day (after breakfast and dinner) for 60 days, and after 6 months, the treatment of cervical dysplasia was investigated.

그 결과는 하기 표 3에 나타내었다.The results are shown in Table 3 below.

시험예 3 결과Test Example 3 result 환자번호Patient number 치료 전Before treatment 치료 후After treatment 1One HPV genotypingHPV genotyping HPV고위험군 33번 검출HPV high risk group 33 detected HPV고위험군 바이러스 미검출
High-risk HPV virus not detected
CervicographyCervicography

Figure 112020080397520-pat00001
Figure 112020080397520-pat00001
Figure 112020080397520-pat00002
Figure 112020080397520-pat00002
22 진단Diagnosis H-SIL/CIN3H-SIL/CIN3 L-SIL/CIN1L-SIL/CIN1 HPV genotypingHPV genotyping HPV고위험군 16번 검출HPV high risk group detected 16 times HPV고위험군 바이러스 미검출
High-risk HPV virus not detected
33 세포병리진단보고서Cell Pathology Diagnosis Report CIN1
Figure 112020080397520-pat00003

CIN1
Figure 112020080397520-pat00003

상피세포 이상소견 없음No abnormal findings of epithelial cells
44 액상세포병리진단Liquid cell pathology diagnosis CIN1
Figure 112020080397520-pat00004
CIN1
Figure 112020080397520-pat00004
NegativeNegative
55 액상세포병리진단Liquid cell pathology diagnosis L-SIL
Figure 112020080397520-pat00005
L-SIL
Figure 112020080397520-pat00005
ASC-USASC-US
HPV genotypingHPV genotyping HPV고위험군 52.56.66번 양성 HPV high risk group 52.56.66 positive HPV고위험군 52번 양성52 positive HPV high risk group 66 액상세포병리진단Liquid cell pathology diagnosis ASC-US
Figure 112020080397520-pat00006
ASC-US
Figure 112020080397520-pat00006
NegativeNegative
77 HPV genotypingHPV genotyping HPV 고위험군 31번양성HPV high risk group 31 positive HPV고위험군 바이러스 미검출High-risk HPV virus not detected 액상세포병리진단Liquid cell pathology diagnosis ASCUSASCUS 상피세포 이상소견 없음No abnormal findings of epithelial cells 88 조직병리진단보고Histopathology diagnosis report CIN3CIN3 CIN1CIN1 99 HPV genotypingHPV genotyping HPV 고위험군 16번양성HPV high risk group No. 16 positive HPV고위험군 바이러스 미검출High-risk HPV virus not detected 액상세포병리진단Liquid cell pathology diagnosis HSIL/CIN3HSIL/CIN3 ASCUSASCUS 1010 액상세포병리진단Liquid cell pathology diagnosis CIN2
Figure 112020080397520-pat00007
CIN2
Figure 112020080397520-pat00007
상피세포 이상소견 없음No abnormal findings of epithelial cells

상기 표 3에서 확인할 수 있는 바와 같이, 본 발명에 의한 실시예 1은 자궁경부이형성증의 치료 및 예방에도 효과가 있는 것으로 확인되었다.As can be seen in Table 3, Example 1 according to the present invention was confirmed to be effective in the treatment and prevention of cervical dysplasia.

상기와 같이, 본 발명의 바람직한 실시 예를 참조하여 설명하였지만 해당 기술 분야의 숙련된 당업자라면 하기의 특허청구범위에 기재된 본 발명의 사상 및 영역으로부터 벗어나지 않는 범위 내에서 본 발명을 다양하게 수정 및 변경시킬 수 있음을 이해할 수 있을 것이다.As described above, the present invention has been described with reference to preferred embodiments of the present invention, but those skilled in the art can variously modify and change the present invention within the scope not departing from the spirit and scope of the present invention described in the following claims. You will understand that you can do it.

Claims (3)

의이인, 창출, 백선피, 고삼, 아레카야자, 무화과나무의 혼합물의 열수추출물을 유효성분으로 포함하며,
상기 열수추출물은, 상기 의이인 100중량부, 창출 50~70중량부, 백선피 30~40중량부, 고삼 30~40중량부, 아레카야자 1~10중량부 및 무화과나무 1~10중량부를 혼합한 후, 이를 물을 용매로 하여 50~130℃에서 3~24시간 추출한 것을 특징으로 하는 질염의 치료 및 자궁경부이형성증의 예방용 한약 조성물.
It contains as an active ingredient a hot water extract of a mixture of Uiyiin, Chunjin, Baekseonpi, Gosam, Areca palm, and Fig tree,
The hot water extract is a mixture of 100 parts by weight of the uiyiin, 50 to 70 parts by weight of creation, 30 to 40 parts by weight of Baekseonpi, 30 to 40 parts by weight of Gosam, 1 to 10 parts by weight of Areca and 1 to 10 parts by weight of fig tree Then, the herbal composition for the treatment of vaginitis and the prevention of cervical dysplasia, characterized in that it is extracted for 3 to 24 hours at 50 to 130 °C using water as a solvent.
삭제delete 제1항에 있어서,
상기 한약 조성물은,
황색포도상구균(Staphylococcus aureus)과 가드네렐라 바지날리스균(Gardnerella vaginalis)에 대한 항균활성 및 칸디다 알비칸스(Candida albicans)에 대한 항진균활성을 갖는 것을 특징으로 하는 질염의 치료 및 자궁경부이형성증의 예방용 한약 조성물.
The method of claim 1,
The herbal composition,
Treatment of vaginitis and prevention of cervical dysplasia, characterized by having antibacterial activity against Staphylococcus aureus and Gardnerella vaginalis and antifungal activity against Candida albicans Chinese herbal medicine composition.
KR1020200095649A 2020-07-31 2020-07-31 Medicinal herbs composition for treating vaginitis and preventing Cervical intraepithelial neoplasia KR102213286B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020200095649A KR102213286B1 (en) 2020-07-31 2020-07-31 Medicinal herbs composition for treating vaginitis and preventing Cervical intraepithelial neoplasia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020200095649A KR102213286B1 (en) 2020-07-31 2020-07-31 Medicinal herbs composition for treating vaginitis and preventing Cervical intraepithelial neoplasia

Publications (1)

Publication Number Publication Date
KR102213286B1 true KR102213286B1 (en) 2021-02-05

Family

ID=74558978

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020200095649A KR102213286B1 (en) 2020-07-31 2020-07-31 Medicinal herbs composition for treating vaginitis and preventing Cervical intraepithelial neoplasia

Country Status (1)

Country Link
KR (1) KR102213286B1 (en)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020062474A (en) * 2001-01-20 2002-07-26 주식회사 네추라 바이오 캠 Composition of herbs having curing effects for vaginitis and lecorrhea, and hygienic pad manufactured using the Composition
KR101133723B1 (en) 2009-10-19 2012-04-09 최원석 Composition comprising salt and sugar for protecting and treating vaginosis disease and the use thereof
KR101771479B1 (en) 2016-12-23 2017-09-05 유한회사 아이에스티케이3 Compositions for preventing and treating vaginitis containing natural plant extracts and sugar as active ingredients
KR101796423B1 (en) * 2017-06-22 2017-12-01 정소용 Composition and ladies genital area cleanser composition comprising composition for inducing Antiviral and antibacterial cause vaginitis and method for manufacturing the same
KR101841137B1 (en) * 2017-01-26 2018-03-23 주식회사 에코마인 Feminine cleanser composition and preparing method thereof
KR20190081046A (en) * 2017-12-29 2019-07-09 주식회사 뉴트라팜텍 Compositions for Feminine Cleanser Comprising Natural Extracts
KR101962641B1 (en) * 2017-11-23 2019-07-31 바이오스펙트럼 주식회사 A antibacterial and antivirus composition containing the extracts of chestnut tree involucre and the feminine cleanser composition comprising the same
KR102014810B1 (en) 2017-09-04 2019-08-27 라임바이오파마 주식회사 Composition for prevention and treatment of vaginitis
KR102090622B1 (en) * 2018-10-26 2020-03-18 박정미 Feminine cleanser and producing method thereof
KR102098824B1 (en) * 2018-06-25 2020-04-22 주식회사 케이와이코스메틱 Cleanser composition for women's vagina and Cleanser for women's vagina containing the same and Manufacturing method thereof

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020062474A (en) * 2001-01-20 2002-07-26 주식회사 네추라 바이오 캠 Composition of herbs having curing effects for vaginitis and lecorrhea, and hygienic pad manufactured using the Composition
KR101133723B1 (en) 2009-10-19 2012-04-09 최원석 Composition comprising salt and sugar for protecting and treating vaginosis disease and the use thereof
KR101771479B1 (en) 2016-12-23 2017-09-05 유한회사 아이에스티케이3 Compositions for preventing and treating vaginitis containing natural plant extracts and sugar as active ingredients
KR101841137B1 (en) * 2017-01-26 2018-03-23 주식회사 에코마인 Feminine cleanser composition and preparing method thereof
KR101796423B1 (en) * 2017-06-22 2017-12-01 정소용 Composition and ladies genital area cleanser composition comprising composition for inducing Antiviral and antibacterial cause vaginitis and method for manufacturing the same
KR102014810B1 (en) 2017-09-04 2019-08-27 라임바이오파마 주식회사 Composition for prevention and treatment of vaginitis
KR101962641B1 (en) * 2017-11-23 2019-07-31 바이오스펙트럼 주식회사 A antibacterial and antivirus composition containing the extracts of chestnut tree involucre and the feminine cleanser composition comprising the same
KR20190081046A (en) * 2017-12-29 2019-07-09 주식회사 뉴트라팜텍 Compositions for Feminine Cleanser Comprising Natural Extracts
KR102098824B1 (en) * 2018-06-25 2020-04-22 주식회사 케이와이코스메틱 Cleanser composition for women's vagina and Cleanser for women's vagina containing the same and Manufacturing method thereof
KR102090622B1 (en) * 2018-10-26 2020-03-18 박정미 Feminine cleanser and producing method thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YUEJUAN LIANG et al., 'A meta-analysis of the relationship between vaginal microecology, human papillomavirus infection and cervical intraepithelial neoplasia', Infectious Agents and Cancer, Vol.14, No.29, Internal pp.1-8 (2019) 1부.* *

Similar Documents

Publication Publication Date Title
CN102160887B (en) Medicament for treating gynecological inflammation and preparation method thereof
US20120245132A1 (en) Composition Comprising Benzoic Acid in Combination with Organic Acid Preservatives as Active Ingredients and the Use Thereof
JP6839329B2 (en) Composition for the management of Helicobacter pylori infection
AU2019100620A4 (en) Preparation of Gel Preparation of Pharmaceutical Composition against Human Papillomavirus and Gynecological Inflammations
MX2012004509A (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof.
CN111084831A (en) Bacteriostatic composition for inhibiting vaginal pathogenic bacteria and application thereof
KR20130046898A (en) Pharmaceutical compositon prevention and treatment of vaginitis and urinary tract infection comprising fermented solution of plant-originated lactic acid bacteria
US20230270797A1 (en) Novel strain of the species lacticaseibadllus rhamnosus, compositions thereof and use thereof in the treatment of genitourinary infections
CN114588253B (en) Pharmaceutical composition for repairing and preventing vaginal mucosa aging and preparation thereof
CN110680855B (en) Vaginal expansion suppository containing probiotics and traditional Chinese medicine composition and preparation method thereof
KR20020062474A (en) Composition of herbs having curing effects for vaginitis and lecorrhea, and hygienic pad manufactured using the Composition
KR102213286B1 (en) Medicinal herbs composition for treating vaginitis and preventing Cervical intraepithelial neoplasia
CN105770682A (en) Suppository for treating colpitis mycotica of pregnant women
CN102743663A (en) Chinese medicinal preparation for treating urinary infection and preparation method thereof
CN113274414A (en) Probiotics preparation for repairing and maintaining vaginal microecological balance
KR101373770B1 (en) Pharmaceutical composition comprising Angelica dahurica Bentham et Hook extract for preventing or treating infectious disease of Enterohamorrhagic Escherichia coli
CN113662998A (en) A pharmaceutical composition for treating vaginitis and gynecological inflammation, and its preparation method
CN111821321A (en) Probiotics composition for nursing female reproductive system
CN110123986B (en) Composition for improving vaginal microecology
CN110227094B (en) Application of albizia julibrissin aqueous extract in preparing external medicine for preventing and treating gynecological inflammatory diseases
EP1646378B1 (en) Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superfinfections and fungal recurrences
Talwar et al. A safe wide spectrum polyherbal microbicide and three meritorious strains of probiotics for regressing infections and restoration of vaginal health (regression of vaginosis with BASANT and probiotics)
KR20240075413A (en) Composition for treating or preventing Cervical intraepithelial neoplasia and vaginosis
CN108785383A (en) A kind of antibacterial gynecology externally used pharmaceutical combination and the preparation method and application thereof
CN108578602B (en) Traditional Chinese medicine composition for treating leukorrheal diseases and preparation method thereof

Legal Events

Date Code Title Description
E701 Decision to grant or registration of patent right
GRNT Written decision to grant